Enhancing Clinical Trial Success
for Pro-Cognitive Drugs in Schizophrenia
Beyond the Horizon of Research on Cognitive Impairment Associated with Schizophrenia (CIAS)
For decades, the pursuit of effective treatments for cognitive impairment associated with schizophrenia (CIAS) has been a persistent challenge within CNS drug development. Despite significant scientific investment and numerous promising compounds, no drugs have yet received regulatory approval for CIAS.
This book explores critical factors contributing to this challenge and provides data-driven strategies to enhance future clinical trial successes.
Key Takeaways
- Deeper understanding of patient stratificationLearn how to identify and select the right patient populations to maximise the detection of pro-cognitive treatment effects, a strategy increasingly crucial for clinical trial success.
- Expert guidance on optimising outcome measures Discover the advantages of advanced digital cognitive assessments and remote monitoring technologies, including speech analysis and wearable sensors, for more sensitive and objective data collection in your trials.
- Practical considerations for refining trial design Explore essential methodological recommendations, from familiarisation sessions to consistent assessment timings and managing the impact of medications, to enhance the accuracy and reliability of your clinical trial results.
Lastest news, publications & insights
Integrating Blood-Based Biomarkers & Digital Cognitive Assessments to Accelerate Brain Health Research
The Convergence: Integrating Blood Biomarker Tests and Digital Cognition to Accelerate Alzheimer’s Research The paradigm for diagnosing and monitoring Alzheimer’s disease (AD) is shifting from...
Bringing Trial Activities to the Participant – Lessons from the RADIAL Proof-of-Concept Trial
Bringing Trial Activities to the Participant Lessons from the RADIAL Proof-of-Concept Trial The move toward more participant-centric clinical research has taken an important step forward....
Speech Analysis as an Objective Biomarker in MDD Trials Speech Biomarkers for Alzheimer’s Disease Show Promise Across Multiple Languages
Speech Biomarkers for Alzheimer’s Disease Show Promise Across Multiple Languages The search for reliable, accessible biomarkers for early detection of cognitive decline has taken an...
CTAD | Posters & Presentations
CTAD | Posters & Presentations Hilton San Diego Bayfront, 1 Park Boulevard – San Diego, CA 92101 | 1-4th December We’re excited to announce we...
